🤝 Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine’s Virtual Disease Models to Rationalize ADC Discovery

Simulate experiments in Turbine's Virtual Lab

Turbine

Turbine's Virtual Lab puts 2.5 trillion simulated experiments at your fingertips, allowing you to rapidly generate novel hypotheses at scale

ADC PAYLOADS
Turbine simulates payloads to match your ADC to the right patients
Contact us Read more



    Close

    TARGET ID
    Turbine uncovers novel targets to expand your pipeline
    Contact us Read more



      Close



        Close

        Scientists have more ideas than ever - our simulation platform helps pick the right ones

        Data science-augmented R&D

        Many hypotheses. Hard to pick.

        Simulation-aided R&D

        Decision engine to select best ideas
        Simulations let you design more experiments to get a more comprehensive answer

        50M+ experiments / day

        • Engineer any sample to simulate
        • Test all relevant perturbations
        moreless
        Simulations are a mechanism engine, showing "why" something occurs

        Mechanistic hypotheses lead to a 50% higher likelihood of validation

        • Select experiments based on mechanistic readouts from our translational toolkit
        • Fail wrong ideas early with Turbine’s in-house validation assays
        moreless
        Simulations base every decision on evidence, boosting PoS

        2x faster timeline from scientific question to validation

        • Integrate pharma knowledge
        • Fit into existing processes
        moreless
        Drag / scroll horizontally for more

        R&D is full of choices - we helped partners make the right ones, repeatedly

        TARGET
        DISCOVERY
        COMBINATION
        DESIGN
        BIOMARKER
        SELECTION
        DISEASE
        POSITIONING
        DRUG
        PHARMACOLOGY
        INDICATION
        EXPANSION
        Impact

        Simulations have shown impact in various programs, at multiple stages of R&D


        APPLICATION AREAS
         
        TARGET
        DISCOVERY
        DRUG
        DISCOVERY

        PRECLINICAL
        EARLY
        DEVELOPMENT
        DEVELOPMENT AND
        COMMERCIALIZATION
        TARGET DISCOVERY
        LATEST NEWS
        TARGET DISCOVERY
        LIG4
        TARGET DISCOVERY
        NEK1
        BIOMARKER SELECTION
        BIOMARKER SELECTION
        DISEASE POSITIONING
        CDC7
        COMBINATION DESIGN
        WEE1
        BIOMARKER SELECTION
        COMBINATION DESIGN
        BIOMARKER SELECTION
        DISEASE POSITIONING
        Top pharma partner
        COMBINATION DESIGN
        DISEASE POSITIONING
        PUBLICATION
        Clear Filters

        Results you can trust quickly delivered, seamlessly integrated into your workflow

        Results you can trust quickly delivered, seamlessly integrated into your workflow Results you can trust quickly delivered, seamlessly integrated into your workflow
        Contact us
        DAVID M. RUBIN PhD
        Managing Director of MSD Global Health Innovation Fund
        “We believe Turbine’s Simulated Cell has the potential to transform key aspects of the oncology drug discovery and development process, providing insight at scale that will shed light on even the most challenging biological mechanisms.”
        SEISHI KATSUMATA
        Corporate Officer / Executive Director, Discovery & Research of Ono Pharmaceutical
        "Turbine has provided multiple targets that have first-in-class potential, along with the biology-driven insights necessary to rapidly validate this potential."
        TOM LOUNIBOS
        Global Managing Director of Accenture Ventures
        "Turbine’s AI-based platform has clearly demonstrated the ability to unlock high-quality biological insights for our clients across the biopharma industry."
        ALAN BARGE
        ex VP and Head of Oncology and Infection at AstraZeneca
        “Turbine can fundamentally change the way in which novel targets in precision oncology are identified.”

        PARTNERS AND INVESTORS



          Close